PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Pharmaceutical

Life Sciences

Biotechnology

PHAXIAM Therapeutics

Thibaut du Fayet

Jonathan Blachier

Daniel Cole

Anne-Cécile Fumey

Frederic Mathat

Elizabeth Todd

Jonathan Barber

Jerome Bailly

Iman El-Hariry

The Research and Development Team at PHAXIAM Therapeutics is dedicated to the discovery and advancement of phage-based therapies targeting resistant bacterial infections. This team conducts laboratory research, leads clinical studies, and manages projects to innovate and optimize treatment options for critical pathogens. Utilizing expertise in microbiology and clinical development, they aim to bring effective solutions to tackle the growing challenge of antibiotic resistance in healthcare settings.

Research and Development Team

Leadership Team

Regulatory Affairs Team

Research and Development Team

About

Team members

Other teams at PHAXIAM Therapeutics

Leadership Team

Regulatory Affairs Team